News

Ajinomoto said based upon a successful proof-of-concept, the company has entered a full licensing agreement that allows for the in-house use of the system. Corynex uses the gram-positive

The licensing agreement provides miRagen with exclusive rights to an important discovery made in collaboration with the University of Glasgow and the University of Cambridge, enabling miRagen to

The agreement aims to manufacture eribulin mesylate as well as other developmental drugs. DSM Pharmaceutical Products president and CEO Alexander Wessels said, "We are delighted to be working

The partnership aims to provide drug developers with improved access to pharmaceutical nanomilling equipment and full pharmaceutical development capabilities. Particle Sciences pharmaceutical development president Robert Lee said the

FDA in the letter mentioned that it requires Mallinckrodt’s complete pharmacokinetic study comparing PENNSAID 2% to original PENNSAID 1.5%. FDA denied to review the similar pharmacokinetic studies submitted

According to the firm, the lower dose submicron diclofenac NDA submission included data from a study conducted on 428 healthy adults in a Phase 3 multi-center, randomized process,

The sNDA filed is to expand the indication for ferumoxytol for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD), who have

As per the alliance, PolyPid will develop the new product, which will be based on BonyPid PolyPid’s product family, that can also treat specific dental problems requiring local,

Earlier to this appointment, Carnegie-Brown served as CEO of Evolutec, a biological drug development business, where he led a successful IPO and established the company’s clinical and manufacturing